Registration for online event

Date: Thursday 19 September 2024
Time: 7:00pm-8:15pm AEST
Venue: Online via Zoom

 

Alexion Registration - 19 September 2024

"*" indicates required fields

Please provide your AHPRA (Australian Health Practitioner Regulation Agency) registration number. Please note: this meeting is for HEALTHCARE PROFESSIONALS ONLY. AHPRA registration details (format: three letters followed by 10 numerals) will be validated for all participants.

Pre-Event Questions

Please help Alexion gauge the educational value of this event by completing this knowledge survey.# The results will be compared to a similar survey completed after the event. All data will be de-identified before analysis. Note this is not an assessment; there are no right or wrong answers.
(1=Limited awareness, 5=Strong awareness)
(1=Not at all confident, 5=Extremely confident)
(1=Not at all confident, 5=Extremely confident)
(Refer to scale description for each option)
5. Which of the following characteristics define a complete response to C5 inhibitor therapy in aHUS?*
(Select all that apply)

Access Recordings of Presentations Post-Event

Tick 'Yes' if you'd like to use your submitted information to simultaneously register for Alexion Assist, a private HCP portal where meeting presentations, case studies, and other aHUS resources can be accessed on-demand. Following the event, you will receive an email with your login details and a temporary password.*

Consent to Receive Electronic Messaging

By ticking the box below, you consent to receiving electronic messages from Alexion regarding the online event for which you are registering and messages from Alexion about rare diseases, approved products and services of Alexion, other scientific information, invitations to events and market research. You have a right to withdraw your consent at any time in the future. If you would like more information regarding how Alexion handles privacy, please view the Alexion Pharmaceuticals Australasia Pty Ltd privacy notice at https://alexion.com/Legal#privacynotice.*

 

ULTOMIRIS® (ravulizumab rch)

 

This medicinal product is subject to additional monitoring in Australia due to approval of an extension of indications. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

Adverse events can also be reported directly to Alexion at https://contactazmedical.astrazeneca.com.
 

WARNING: SERIOUS MENINGOCOCCAL INFECTION.

Ultomiris increases the risk of meningococcal infections. Life-threatening meningococcal infections/sepsis have occurred in patients treated with Ultomiris. Meningococcal infection may become rapidly life-threatening or fatal if not recognised and treated early. Immunise patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of Ultomiris, unless the risks of delaying Ultomiris therapy outweigh the risk of developing a meningococcal infection. Refer to the most current edition of the Australian Immunisation Handbook for meningococcal vaccination guidelines. Patients who initiate Ultomiris treatment less than 2 weeks after receiving meningococcal vaccination must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. Vaccination reduces, but does not eliminate, the risk of meningococcal infections. Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected. Patients should be advised about the signs and symptoms of meningococcal infection and to seek medical care immediately if they occur.

 

Ensure immunisation currency; patients below the age of 18 years old must be vaccinated against Haemophilus influenzae and pneumococcal infections.

 

PBS Information: Ultomiris® is listed on the PBS as a Section 100 item for the treatment of atypical Haemolytic Uraemic Syndrome (aHUS). Refer to PBS Schedule for full authority information.

 

Please refer to the full Ultomiris® Product Information before prescribing, which can be accessed at https://rss.medsinfo.com.au/xi/pi.cfm?product=xipultoi

 

This educational event, organised by Alexion, is intended for health professionals only. Alexion medicines in the context of aHUS management will be discussed. All content is developed by the presenters for the meeting in collaboration with Alexion. Alexion has reviewed the materials for scientific accuracy, fair balance and for regulatory compliance purposes. All costs will be at the participants’ own expense. Attendees are responsible for obtaining approval to receive and/or disclose hospitality as required by their employer or professional association. Alexion does not subsidise or pay for the hospitality of those associated with delegates attending events. Alexion reserves the right to decline access to participants who are not involved in the management of patients who are on Alexion therapies. All attendance at Alexion-sponsored events is documented.

Please be aware this meeting will be recorded.

#The Survey is conducted by Alexion. The purpose of collecting, storing, using and analysing information relating to you is to survey the current understanding of the management of aHUS. The aggregated results will be compared to the post event results from a similar survey, and analysed to demonstrate the value of the educational event, and to identify educational needs for future activities. The information you provide will be used only for the purpose described above, unless otherwise agreed in writing with you. For your participation to this survey, we collect and use the following personal data: state, profession, specialty, and answers to the survey questions

Alexion recognises the importance of protecting the privacy of personal information it collects and respects your rights to privacy under the Privacy Act 1988 (Cth). If you require further information about how Alexion collects, uses, shares and protects information please see the full Privacy Notice at https://alexion.com/Legal#privacynotice. If you would like to withdraw your consent for inclusion on Alexion mailings, or would like to access your personal information, please email the Privacy Officer at privacyofficer.austraIia@alexion.com.

© 2024. All rights reserved. Alexion Pharmaceuticals Australia Pty Ltd. ACN 132 343 036. 66 Talavera Road, Macquarie Park, NSW 2113 Australia. August 2024. AU/ULT-a/0054.